Last updated: May 25, 2026
Captopril suppliers: What manufacturers supply captopril API and finished dosage forms globally
Captopril supply is split between (1) contract manufacturers producing finished tablets and (2) API producers making captopril (drug substance) for branded and generic markets. For business planning and IP risk, the key fact is that captopril is a long-established generic chemical with deep global sourcing; most procurement programs rely on multiple API and dosage-form suppliers to manage price and continuity risk.
Quick supply map (who typically supplies what)
- API producers (captopril drug substance): chemical manufacturers in India and China are the dominant global volume suppliers.
- Finished dosage form (tablets): tablet makers in multiple countries procure API and convert to generic captopril strengths via standardized oral solid processes.
- Branded supply (historical): originator-era manufacturing is now mostly supplied via generics and authorized generics in most markets.
Note: The supplier list depends on the country, strength, and whether you source API, intermediates, or finished tablets. Without an identified market and dosage form specification, listing a definitive “top suppliers” roster risks being incomplete.
What companies supply captopril API and where are they based?
Featured snippet answer: Captopril API is supplied globally, with the largest supplier density in India and China, supplemented by European and US specialty/secondary sources that support branded or higher-spec regulatory needs.
API supply characteristics
- Common sourcing model: API manufacturer sells captopril to generic formulators under DMF/ASMF-driven regulatory submissions.
- Regulatory artifact depends on jurisdiction: EU uses ASMF; US uses DMF (Type II/III depending on filing structure).
- Quality system emphasis: CoA testing and impurity profile control matter because captopril is sensitive to process-related impurities, including disulfide and related degradation products.
Typical API buyer requirements
- DMF/ASMF access for regulatory file linkage
- Stability package and validated shelf-life data
- Impurity specifications and analytical method package
- GMP audit readiness (or written audit summary)
- Serialization/packaging requirements where applicable
Which manufacturers supply captopril tablets (finished dosage forms) by strength?
Featured snippet answer: Finished captopril tablets are widely available from generic pharmaceutical manufacturers, usually in 12.5 mg, 25 mg, and 50 mg strengths, with procurement driven by local approvals and tender pricing.
Dosage-form supply considerations
- Bioequivalence driven: oral solid captopril generics rely on dissolution and BE testing where required.
- Packaging options: bottle packaging is common; unit-dose packaging varies by country procurement rules.
- Tablet composition: excipient selection differs by manufacturer and can influence dissolution profiles and impurity control.
How buyers segment suppliers
- Low-cost tenders: prioritize price-per-tablet and supply continuity.
- Tender compliance: require regulatory status alignment (approved marketing authorizations) and batch release documentation.
- Hospital procurement: emphasizes consistent tablet appearance, stability claims, and distribution reliability.
How many captopril suppliers exist worldwide for API and tablets?
Featured snippet answer: The supplier universe is large because captopril is a mature generic molecule. In practice, buyers use a short list of approved suppliers tied to regulatory files, not the entire global market.
Practical supplier count logic
- API supplier pool: typically dozens globally, but only a subset supports relevant regulatory dossiers in target jurisdictions.
- Finished dose pool: often more numerous due to local generic manufacturers.
When do captopril suppliers face supply risk or shortages?
Featured snippet answer: Supply risk is most likely when API production capacity is constrained by raw-material availability, corrosion-sensitive equipment downtime, or regulatory actions affecting specific DMF/ASMF files. For captopril, generic sourcing volatility tracks broader China-India API cycle risk.
Risk indicators procurement teams monitor
- sudden API price increases for sulfhvdrλ-precursor and thiol chemistry chain items (chemical feed volatility)
- audit findings at specific API sites
- recall history at tablet manufacturing sites
- discontinuation notices for low-volume strengths
What quality/regulatory dossiers link suppliers to captopril approval in the US and EU?
Featured snippet answer: US approvals rely on linked DMFs in the FDA system, while EU approvals rely on linked ASMFs in the European regulatory framework.
What suppliers need to provide
- DMF/ASMF reference number(s) and compliance status
- batch production record summaries upon inspection
- impurity profile: limits, trends, and method validation
- container-closure system compatibility data
Which captopril suppliers are most relevant to Paragraph IV or exclusivity disputes?
Featured snippet answer: Paragraph IV challenges typically matter less for captopril because it is off-patent in most major markets, so supplier competition is usually driven by formulation equivalence, quality, and file strategy rather than active brand exclusivity.
Implication for supply
- Most “entry” disputes are less about molecule patents and more about regulatory file alignment and manufacturing compliance.
How does captopril supplier selection affect API impurity profile and batch release?
Featured snippet answer: Supplier changes can shift impurity profile and dissolution performance, which can drive batch rejections if specs are not aligned.
Operational controls buyers use
- establish incoming acceptance specs at purchase
- require method transfer or at least analytical method comparability
- run three-way comparison on dissolution for tablet makers
- lock impurity limits by stability-indicating method
How does captopril supplier pricing usually work (API vs tablets)?
Featured snippet answer: API pricing drives a large portion of finished product cost; finished tablet pricing then reflects regulatory filing, excipients, packaging, and tender/contract structure.
What changes cost
- API yield and impurity remediation costs
- conversion cost (tablet compression), packaging line capacity
- freight and tariff volatility
- local regulatory fees and batch release testing
Supplier due diligence checklist for captopril (API and tablets)
Featured snippet answer: Use a two-track diligence package: regulatory file linkage plus GMP process control verification.
API diligence
- DMF/ASMF reference readiness and cross-reference to your target jurisdiction
- impurity trend history
- stability protocol and real-time stability updates
- equipment and cleaning validation capability for thiol-reactive chemistry
Finished-dose diligence
- dissolution profile and BE package history
- tablet hardness and friability specs
- batch release testing method set
- packaging and label compliance procedures
Key Takeaways
- Captopril supply is dominated by global generic sourcing, with dense API production in India and China and wide finished tablet manufacturing worldwide.
- Procurement should be structured around regulatory dossier linkage (DMF/ASMF) and quality/spec alignment, not broad market name recognition.
- Supplier transitions can change impurity and dissolution performance, creating batch-release risk unless acceptance specs and comparability studies are in place.
- For captopril, market entry dynamics are typically file and compliance driven, with less impact from molecule-level exclusivity.
FAQs
1) Who typically manufactures captopril API for generic companies?
Captopril API is most commonly produced by large-scale chemical manufacturers serving multiple generic brands, concentrated in India and China with some regional secondary suppliers.
2) Are captopril tablets universally interchangeable across countries?
Not automatically. Interchangeability depends on local approvals, labeling, tablet specs, and dissolution performance; procurement typically uses approved marketing authorization status and BE/equivalence documentation.
3) What documents should a captopril API supplier provide for regulatory submissions?
DMF/ASMF reference details, impurity specifications, stability data, and method/analytical package support aligned to the target regulator.
4) What are common reasons captopril batches fail release after switching suppliers?
Differences in impurity profile, dissolution behavior, stability drift, or method-to-method discrepancies versus your internal acceptance criteria.
5) Does captopril supply risk relate more to tablet manufacturing or API production?
Most continuity risk traces back to API production constraints, with tablet manufacturing risk driven by quality-system events and batch release disruptions.
References
No citable sources were provided in the prompt, and no market-specific regulator listings (FDA Orange Book, EU registers, or supplier registries) were supplied.
